Wockhardt Files EMA Application for Novel Antibiotic WCK 5222

13 Jan 2026 CW Team

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.

The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.

Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Real Estate

02 Feb 2026

Union Budge: Infra-Led Urban Shift

The Union Budget FY27 reinforces infrastructure-led urbanisation as the backbone of India’s real estate and housing growth. Higher public capital expenditure, City Economic Regions, risk-mitigation mechanisms and REIT-led asset monetisation are being widely viewed as long-term enablers, even as the industry continues to seek sharper supply-side reforms and affordability-focused measures. Here are a few industry insights:Dr Niranjan Hiranandani, Chairman, NAREDCO & Hiranandani Group“The Union Budget 2026-27 is growth-oriented and stability-focused, supporting consumption and aiming to s..

Budget 2026 Charts Path for Infrastructure-Led, Tech-Driven Growth

The Union Budget 2026–27 signals strong continuity in India’s macroeconomic strategy, anchored in elevated public capital expenditure, fiscal discipline, and a sharper focus on manufacturing, infrastructure, and regional development. With capital outlay pegged at ₹12.2 lakh crore and a fiscal deficit target of around 4.3 per cent, the Budget balances growth ambition with stability, offering long-term visibility to investors and project developers.A dominant theme is the centrality of infrastructure as a multiplier for economic expansion. Public capex now accounts for over 3.3 per cent of..

Tata Power Arm Crosses 10 GW EPC Milestone

Tata Power Renewable Energy Ltd (TPREL) has achieved a major milestone by executing 10 gigawatts of engineering, procurement and construction (EPC) renewable energy projects to date, reinforcing its position in India’s clean energy infrastructure sector. According to the company, the executed portfolio comprises 4.2 gigawatts of in-house projects and 5.8 gigawatts of third-party projects. Of the total 10 gigawatts commissioned so far, 9.7 gigawatts are solar projects and 290 megawatts are wind projects. In the first nine months of FY26, TPREL commissioned 1.88 gigawatts of EPC renewable en..